



Investor's Presentation



Table Of Contents

- [Company Overview](#)
- [Mission & Vision](#)
- [Core Business](#)
- [Goals & Strategy](#)
- [Key Products](#)
- [Production Volumes](#)
- [Revenue](#)
- [Our Team](#)
- [Our Clients](#)
- [Safe Harbor Statement](#)
- [Thank you](#)



SYSCHEM
INDIA

Company Overview

- Syschem (India) Limited (SIL) is a listed company engaged in the manufacturing of Bulk Drugs/Intermediates and contract manufacturing. It is owned and operated by a highly committed group of techno commercial with extensive experience in the bulkdrug business.



- The Company is committed by its highly committed group of techno-commercial experts with extensive experience in the bulk drug industry. With their expert knowledge and dedicated approach, Syschem India Limited has been able to establish a strong foothold in the industry and offer high-quality products and services to their customers.
- The Company's focus on research and development, quality assurance and customer satisfaction has helped it to build a reputation as a reliable and trusted partner in the Pharmaceuticals industry.



Mission & Vision



The revenue growth comes from three factors -

- Largely the capacity expansions
-

- Increase in distribution network
-

- Adding Product Ranges

[Back to Agenda Page](#)

SIL's Vision is to increase the production of our existing products and expand our offerings by producing several intermediates that are currently imported from China for API industries. Over the next 2-3 years, we aim to reduce our dependency on imports and achieve greater self-sufficiency.


To accomplish this, we recognize the need to expand our plant and machinery. We believe this investment will propel us towards our goal and set us up for long-term success.

[Back to Agenda Page](#)

Core Business

The Company has diversified intermediates products in the Pharmaceuticals which are produced by the chemical route we have a wide range for the formulation Pharmaceuticals Industry.


The Company has marked its presence in India and the International market its products have been exported to Latin America, Africa, Thailand, Egypt, Sri Lanka, Germany, Bangladesh, and MENA region.



Supply Zone


Syschem has established its supply chain across 11 states in India and expanded its reach to more than 7 international regions.

Our commitment to delivering quality products has enabled us to become a trusted supplier domestically and internationally.



Core Business

[Back to Agenda Page](#)



Supply Zone

We continue to expand our operations and reach to better serve our customers and provide them with the highest level of satisfaction.

Goals & Strategy

[Back to Agenda Page](#)

The goal of the pharmaceutical Active Pharmaceutical Ingredient (API) industry is to produce high-quality, safe, and effective raw materials for the manufacture of drugs and other healthcare products. The industry's strategy to achieve this goal involves several key elements:



Research and Development (R&D):

The API industry invests heavily in R&D to develop new and innovative processes for the production of APIs. This includes the use of advanced technologies, such as continuous manufacturing, to improve efficiency and reduce costs.



Quality Control

The API industry adheres to stringent quality control measures, including Good Manufacturing Practices (GMP), to ensure that APIs are of the highest quality and meet regulatory requirements.



Regulatory Compliance

The API industry works closely with regulatory agencies to ensure that APIs meet regulatory requirements and are safe for use in pharmaceutical products.



Sustainability

The API industry recognizes the importance of sustainability and is committed to minimizing its environmental footprint through sustainable sourcing practices, reducing waste and emissions, and optimizing energy and water usage.

Supply Chain Management:

The API industry focuses on optimizing its supply chain to ensure a reliable and consistent supply of raw materials for the pharmaceutical industry.

The API industry's strategy also involves collaboration with other stakeholders in the pharmaceutical industry, including drug manufacturers, regulatory agencies, and healthcare providers. By working together, the industry can ensure the development of safe, effective, and affordable medicines for patients around the world.



KEY PRODUCTS

Amoxicillin

Amoxicillin is a widely used antibiotic belonging to the penicillin group of antibiotics.



Dicloxacillin

Dicloxacillin is an antibiotic belonging to the penicillin group of antibiotics, specifically classified as a semi-synthetic penicillinase-resistant penicillin



Ampicillin

Ampicillin is a type of antibiotic that is commonly used to treat bacterial infections.



Flucloxacillin

Flucloxacillin is a type of antibiotic that is commonly used to treat bacterial infections




Cloxacillin

Cloxacillin is a type of antibiotic that is commonly used to treat bacterial infections



Cephalexin

Cephalexin is a type of antibiotic that is commonly used to treat bacterial infections.



KEY PRODUCTS

Cephadroxil

Cephadroxil is a type of antibiotic that belongs to the cephalosporin family. It works by inhibiting the growth of bacteria and preventing them from reproducing.



Cefaclor


Cefaclor works by inhibiting the growth of bacteria and preventing them from reproducing.

"Our aim is to increase
Production on year to year
basis to achieve our target."




[Back to Agenda Page](#)


PRODUCTION VOLUME CURRENT YEAR




QUARTER 1



QUARTER 2



QUARTER 3



QUARTER 4

PRODUCTION VOLUME YEARLY

2022

FY 21 - 22

Product Volume for Financial Year 2022 has been 435 Metric Tonnes

2023

FY 22 - 23

Product Volume for Financial Year 2022 has been 559 Metric Tonnes

FY 22 - 23
559 MT



FY 21 - 22
435 MT

"Pharmaceutical Sales involve promoting and selling medications to healthcare professionals and institutions to improve patient outcomes and drive Revenue growth for the company."




[Back to Agenda Page](#)

SALES & EBIDTA CURRENT YEAR



QUARTER 1



QUARTER 2



QUARTER 3



QUARTER 4

EBIDTA



₹1.4
Crores



₹2.1
Crores



₹2.8
Crores



₹2.6
Crores

SALES & EBIDTA CONSOLIADATED

2022


FY 21 - 22

SALES - ₹ 66 Cr.
EBIDTA - ₹ 69 Lkhs

2023

FY 22 - 23

SALES - ₹ 130.6 Cr.
EBIDTA - ₹ 8.89 Cr



Sales Report 2023

Margins & PAT

₹8 Cr. A Year Increase Rate

"Our innovative medications, data-driven strategies, and strong partnerships have driven significant revenue growth for our pharmaceutical company."

PBT


MARGINS (PBT)

FY 22 - ₹ -2.17 Cr.
FY 23 - ₹ 6.15 Cr.

PAT


PROFIT AFTER TAX

FY 22 - ₹ -1.71 Cr.
FY 23 - ₹ 4.51 Cr.



[Back to Agenda Page](#)

CURRENT YEAR GROWTH



Production Growth

Sil's Production has inc. by 29% over the last financial year (22 - 23)



Revenue Growth


Sil's revenue has inc. by 99% over the last financial year (22 - 23)



EBIDTA Growth

Sil's EBIDTA has inc. by 1186 over the last financial year (22 - 23)

CURRENT YEAR GROWTH



PBT Growth

Sil's Profit Before Tax has inc. by 383% over the last financial year (22 - 23)



PAT Growth

Sil's Profit After Tax has inc. by 364% over the last financial year (22 - 23)

Sales Report 2023

OUR TEAM



The backbone of the Indian Pharmaceuticals industry is the bulk drug industry and in the past, a well-developed bulk drugs sector ensured that India remained self-dependent on its intermediates and active pharmaceuticals ingredients (APIs)

"Impressive revenue growth has been a hallmark of our API Producing pharmaceuticals company, driven by our commitment to producing high-quality, affordable products that meet the needs of our customers and contribute to better health outcomes."

OUR CLIENTS



LABORATE
PHARMACEUTICALS INDIA LTD



RIVPRA

HimalayaTM
SINCE 1930



Yeluri



MAXMED LIFE SCIENCES PVT. LTD.

[Back to Agenda Page](#)

SAFE HARBOR STATEMENT

This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, reliability, or fairness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of or any omission from this Presentation is expressly excluded. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Presentation or in relation to the bases and assumptions underlying such projections. You must satisfy yourself in relation to the reasonableness, achievability, and accuracy thereof.

[Back to Agenda Page](#)

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the wind power industry in India and worldwide, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences, and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance, or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company, and the Company is not responsible for such third-party statements and projections.

No responsibility or liability is accepted for any loss or damage, howsoever arising, that you may suffer as a result of this Presentation. All responsibility and liability are expressly disclaimed by the Management, the Shareholders, and the Company or any of them or any of their respective directors, officers, affiliates, employees, advisers, or agents.

[Back to Agenda Page](#)

THANK YOU

A Presentation by -



Factory at. : Village Bargodam, Tehsil Kalka, Dist. Panchkula, Haryana-133302

Corp Office. : 825, FF, NAC Manimajra , Chandigarh-161001

Email : info@syschem.in

Contact. : 91-9910489212

[Back to Agenda Page](#)